Editas Medicine (EDIT)
Market Price (4/13/2026): $2.94 | Market Cap: $286.2 MilSector: Health Care | Industry: Biotechnology
Editas Medicine (EDIT)
Market Price (4/13/2026): $2.94Market Cap: $286.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -45% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -87%, 3Y Excs Rtn is -124% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -99 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -245% Stock price has recently run up significantly12M Rtn12 month market price return is 126% Weak revenue growthRev Chg QQuarterly Revenue Change % is -19% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -408%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -409% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -60% Key risksEDIT key risks include [1] significant technical and regulatory hurdles for its unproven in vivo gene-editing approach, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -45% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -87%, 3Y Excs Rtn is -124% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -99 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -245% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 126% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -19% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -408%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -409% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -60% |
| Key risksEDIT key risks include [1] significant technical and regulatory hurdles for its unproven in vivo gene-editing approach, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Editas Medicine (EDIT) stock has gained about 45% since 12/31/2025 because of the following key factors:
1. Strong Preclinical Data and Pipeline Advancement for EDIT-401.
Editas Medicine announced compelling preclinical data for its lead in vivo development candidate, EDIT-401, in March 2026. This candidate, targeting heterozygous familial hypercholesterolemia (HeFH), demonstrated over 90% mean LDL-C reduction in non-human primate studies, exceeding standard of care therapies that typically show 40%-60% reduction. The company is on track to submit an Investigational New Drug (IND)/Clinical Trial Application (CTA) by mid-2026 and initiate a first-in-human clinical trial with early human proof-of-concept data expected by year-end 2026.
2. Positive Analyst Sentiment and Price Target Upgrades.
Analysts have shown increased optimism for Editas Medicine since the end of 2025. In March 2026, Jones Trading upgraded Editas Medicine to a "Buy" rating with a price target of $8.00. The consensus among 8 Wall Street analysts as of April 9, 2026, is a "Moderate Buy," with an average 12-month price target of $5.30, representing a significant potential upside of approximately 84.99% from its price around $2.87.
Show more
1. Strong Preclinical Data and Pipeline Advancement for EDIT-401.
Editas Medicine announced compelling preclinical data for its lead in vivo development candidate, EDIT-401, in March 2026. This candidate, targeting heterozygous familial hypercholesterolemia (HeFH), demonstrated over 90% mean LDL-C reduction in non-human primate studies, exceeding standard of care therapies that typically show 40%-60% reduction. The company is on track to submit an Investigational New Drug (IND)/Clinical Trial Application (CTA) by mid-2026 and initiate a first-in-human clinical trial with early human proof-of-concept data expected by year-end 2026.
2. Positive Analyst Sentiment and Price Target Upgrades.
Analysts have shown increased optimism for Editas Medicine since the end of 2025. In March 2026, Jones Trading upgraded Editas Medicine to a "Buy" rating with a price target of $8.00. The consensus among 8 Wall Street analysts as of April 9, 2026, is a "Moderate Buy," with an average 12-month price target of $5.30, representing a significant potential upside of approximately 84.99% from its price around $2.87.
Show more
Stock Movement Drivers
Fundamental Drivers
The 43.4% change in EDIT stock from 12/31/2025 to 4/12/2026 was primarily driven by a 77.4% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.05 | 2.94 | 43.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 46 | 41 | -12.6% |
| P/S Multiple | 4.0 | 7.1 | 77.4% |
| Shares Outstanding (Mil) | 90 | 97 | -7.5% |
| Cumulative Contribution | 43.4% |
Market Drivers
12/31/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| EDIT | 43.4% | |
| Market (SPY) | -5.4% | 37.9% |
| Sector (XLV) | -4.8% | 45.6% |
Fundamental Drivers
The -15.3% change in EDIT stock from 9/30/2025 to 4/12/2026 was primarily driven by a -13.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.47 | 2.94 | -15.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 39 | 41 | 4.2% |
| P/S Multiple | 7.5 | 7.1 | -6.2% |
| Shares Outstanding (Mil) | 84 | 97 | -13.3% |
| Cumulative Contribution | -15.3% |
Market Drivers
9/30/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| EDIT | -15.3% | |
| Market (SPY) | -2.9% | 33.1% |
| Sector (XLV) | 6.3% | 32.5% |
Fundamental Drivers
The 153.4% change in EDIT stock from 3/31/2025 to 4/12/2026 was primarily driven by a 138.2% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.16 | 2.94 | 153.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32 | 41 | 25.4% |
| P/S Multiple | 3.0 | 7.1 | 138.2% |
| Shares Outstanding (Mil) | 83 | 97 | -15.1% |
| Cumulative Contribution | 153.4% |
Market Drivers
3/31/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| EDIT | 153.4% | |
| Market (SPY) | 16.3% | 37.4% |
| Sector (XLV) | 2.3% | 39.3% |
Fundamental Drivers
The -59.4% change in EDIT stock from 3/31/2023 to 4/12/2026 was primarily driven by a -72.1% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.25 | 2.94 | -59.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20 | 41 | 105.6% |
| P/S Multiple | 25.3 | 7.1 | -72.1% |
| Shares Outstanding (Mil) | 69 | 97 | -29.3% |
| Cumulative Contribution | -59.4% |
Market Drivers
3/31/2023 to 4/12/2026| Return | Correlation | |
|---|---|---|
| EDIT | -59.4% | |
| Market (SPY) | 63.3% | 30.0% |
| Sector (XLV) | 19.1% | 27.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EDIT Return | -62% | -67% | 14% | -87% | 61% | 41% | -96% |
| Peers Return | 10% | -39% | 9% | -36% | 7% | 14% | -43% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| EDIT Win Rate | 17% | 33% | 50% | 17% | 67% | 75% | |
| Peers Win Rate | 37% | 42% | 47% | 40% | 57% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| EDIT Max Drawdown | -62% | -69% | -30% | -88% | -23% | -19% | |
| Peers Max Drawdown | -25% | -50% | -28% | -40% | -34% | -11% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRSP, NTLA, BEAM, VRTX, CRBU. See EDIT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | EDIT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.1% | -25.4% |
| % Gain to Breakeven | 1349.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -54.6% | -33.9% |
| % Gain to Breakeven | 120.3% | 51.3% |
| Time to Breakeven | 98 days | 148 days |
| 2018 Correction | ||
| % Loss | -58.7% | -19.8% |
| % Gain to Breakeven | 142.3% | 24.7% |
| Time to Breakeven | 719 days | 120 days |
Compare to CRSP, NTLA, BEAM, VRTX, CRBU
In The Past
Editas Medicine's stock fell -93.1% during the 2022 Inflation Shock from a high on 1/8/2021. A -93.1% loss requires a 1349.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Editas Medicine (EDIT)
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
AI Analysis | Feedback
Moderna for genetic diseases, but using CRISPR gene-editing technology.
An early-stage Intel for the human genome, building foundational CRISPR tools to repair DNA.
The Adobe of human DNA, developing powerful CRISPR tools to precisely edit and correct disease-causing genes.
AI Analysis | Feedback
- EDIT-101: A gene-editing therapy in clinical trials for Leber Congenital Amaurosis 10, an inherited childhood blindness.
- EDIT-102: A gene-editing therapy in development for Usher Syndrome 2A and autosomal dominant retinitis pigmentosa, both affecting vision and sometimes hearing.
- EDIT-301: A gene-editing therapy designed to treat sickle cell disease and transfusion-dependent beta-thalassemia.
- Gene-edited Natural Killer (NK) cell medicines: Therapies under development that modify NK cells to treat solid tumor cancers.
- Alpha-beta T cell therapies: Gene-edited T cell therapies being developed for various cancers.
- Gamma delta T cell therapies: Gene-edited T cell therapies in development for treating different types of cancer.
- Neurological disease therapy (Early Discovery): A therapy in early discovery stages aimed at treating a specific neurological disease.
AI Analysis | Feedback
Editas Medicine (EDIT) is a clinical-stage genome editing company focused on developing genomic medicines. As such, it does not currently sell approved products directly to individuals (patients). Instead, its primary "customers" are other companies with which it forms strategic alliances and research collaborations for the development and potential commercialization of its therapies. These collaborations often involve upfront payments, milestone payments, and future royalties, which represent Editas Medicine's revenue streams from these partners.
Based on the provided information, Editas Medicine's major corporate partners (customers) include:
- Juno Therapeutics, Inc.
- Allergan Pharmaceuticals International Limited
- Asklepios BioPharmaceutical, Inc. (AskBio)
AI Analysis | Feedback
nullAI Analysis | Feedback
Gilmore O'Neill, President and Chief Executive Officer
Gilmore O'Neill joined Editas Medicine as President and Chief Executive Officer in June 2022. He brings over 20 years of experience in genetic medicine, neurobiology, and clinical development. Prior to Editas, Dr. O'Neill served as Executive Vice President of Research & Development and Chief Medical Officer at Sarepta Therapeutics from 2018 to 2021. He also spent 15 years at Biogen, where his roles included Senior Vice President, Late Stage Clinical Development. He has a track record of driving successful clinical programs and achieving marketing approvals for several medicines, including Amondys®, Vyondys®, Spinraza®, Plegridy®, and Tecfidera®. He currently serves as a Director at Unity Biotechnology.
Amy Parison, Chief Financial Officer
Amy Parison was appointed Chief Financial Officer of Editas Medicine in March 2025, succeeding Erick J. Lucera. She joined Editas Medicine in August 2022 and has held multiple roles of increasing responsibility within the company, including Senior Vice President of Finance, Vice President of Finance, and Corporate Controller. Prior to her tenure at Editas, Ms. Parison was the Corporate Controller at Rubius Therapeutics, Inc., and held various financial roles at Vertex Pharmaceuticals.
Linda C. Burkly, Ph.D., Chief Scientific Officer
Linda C. Burkly joined Editas Medicine as Chief Scientific Officer in July 2023. She is responsible for leading the company's drug discovery team and activities across all therapeutic areas. Dr. Burkly brings more than 35 years of experience in biotechnology as a research leader, with expertise spanning drug discovery and development in immunological, neurological, and rare genetic disorders. She spent 37 years at Biogen, where she contributed to the foundations of approved medicines and late-stage programs, including the multiple sclerosis treatment Tysabri.
Brieana Buckley, Senior Vice President, Development and Program Leadership
Brieana Buckley serves as the Senior Vice President, Development and Program Leadership at Editas Medicine. She is a member of the executive leadership team responsible for advancing the company's experimental medicines.
Frank Panaccio, Senior Vice President and Chief Business Officer
Frank Panaccio is the Senior Vice President and Chief Business Officer at Editas Medicine. He is part of the executive leadership team responsible for business development and strategic initiatives for the company.
AI Analysis | Feedback
```html
- Clinical Development and Regulatory Approval Risk: As a clinical-stage genome editing company, Editas Medicine's success is critically dependent on the successful outcome of its ongoing and future clinical trials for drug candidates such as EDIT-101, EDIT-102, and EDIT-301. Failure to achieve favorable results in these trials, significant delays, or unforeseen safety concerns would severely impact the company's ability to develop and commercialize its medicines. Even with successful clinical data, there is a substantial risk of not obtaining the necessary regulatory approvals from health authorities for these novel gene editing therapies.
- Intellectual Property and Patent Disputes: Editas Medicine's proprietary gene editing platform is based on CRISPR technology. The field of CRISPR technology is characterized by complex and often contentious intellectual property landscape, with numerous ongoing patent disputes and litigation among various entities. The company's ability to operate, develop, and commercialize its products hinges on its ability to maintain and defend its intellectual property rights and navigate potential challenges from competitors regarding patent infringement or ownership.
AI Analysis | Feedback
null
AI Analysis | Feedback
Addressable Markets for Editas Medicine's Main Products
Editas Medicine, Inc. focuses on developing genomic medicines for serious diseases. The addressable markets for their main products and services are as follows:
- Leber Congenital Amaurosis 10 (LCA10) - EDIT-101: The global market for Leber Congenital Amaurosis is estimated to be valued at approximately USD 1.29 billion in 2025 and is projected to reach USD 1.78 billion by 2032. North America is expected to account for an estimated 39.8% of this market in 2025. EDIT-101 specifically targets the IVS26 CEP290 mutation, which affects about 1,500 patients in the U.S.
- Usher Syndrome 2A - EDIT-102: The global Usher Syndrome market is estimated to be valued at approximately USD 2.29 billion in 2025 and is expected to reach USD 3.20 billion by 2032. North America is projected to lead this market, holding a 38.2% share in 2025. More specifically for Usher Syndrome Type 2, the global market size was valued at USD 1.35 billion in 2024 and is expected to reach USD 2.15 billion by 2032, with North America dominating at approximately 39.6% of the global market share in 2025.
- Autosomal Dominant Retinitis Pigmentosa: The global Retinitis Pigmentosa market size is projected to grow from approximately USD 14.27 billion in 2024 to USD 30.69 billion by 2035. In 2022, between 82,500 and 110,000 individuals in the United States were affected by retinitis pigmentosa. The total Retinitis Pigmentosa treatment market size in the U.S. was estimated to be nearly USD 260 million in 2023. Autosomal dominant retinitis pigmentosa accounts for 20-25% of nonsyndromic retinitis pigmentosa cases.
- Sickle Cell Disease - EDIT-301: The global sickle cell disease treatment market size was estimated at approximately USD 2.75 billion in 2023 and is projected to reach USD 7.42 billion by 2030. Other estimates place the global market size at USD 3.94 billion in 2025, reaching USD 20.47 billion by 2034. North America dominated the global market with a 37.87% share in 2023, and the United States alone held a 63.35% market share in 2025.
- Transfusion-Dependent Beta-Thalassemia - EDIT-301: The global thalassemia market size was valued at approximately USD 850.0 million in 2023 and is projected to grow at a CAGR of 7.8% from 2024 to 2030. The beta-thalassemia segment constituted 71.2% of the revenue share in 2023, and its market size is expected to reach USD 822.5 million by 2034 from USD 340.3 million in 2023. North America held the largest share of the global thalassemia market, at 42.8% in 2023.
- Gene-Edited Natural Killer (NK) Cell Medicines for Solid Tumor Cancers: The global natural killer (NK) cell therapeutics market size was estimated at USD 340.25 million in 2024 and is predicted to increase to approximately USD 9,997.65 million by 2034. The cancer segment held the largest share in the NK cell therapeutics market in 2024. The CAR-NK cell therapy market was valued at USD 2.16 billion in 2024 and is projected to reach USD 3.10 billion by 2032, with the U.S. currently dominating.
- Alpha-Beta T Cells for Multiple Cancers: The global T-cell immunotherapy market size was approximately USD 8.43 billion in 2025 and is predicted to increase to USD 26.53 billion by 2034. Another estimate places the T-cell immunotherapy market at USD 3.94 billion in 2025, rising to USD 32.75 billion by 2030. North America held the largest share of the T-cell therapy market, at 63.88% in 2022. The cancer gene therapy market, which includes T-cell therapies, was valued at USD 24.96 billion in 2025 and is estimated to grow to USD 67.11 billion by 2031, with solid tumors projected to advance at a 27.29% CAGR between 2026 and 2031.
- Gamma Delta T Cell Therapies to Treat Cancer: The gamma delta T cell cancer therapy market size was USD 2.11 billion in 2025 and is projected to reach USD 4.94 billion by 2030. North America was the largest region in this market in 2025.
- Therapy to Treat a Neurological Disease (Early Discovery Program): The gene therapy market for neurological diseases was valued at USD 3.13 billion in 2024 and is expected to grow to USD 5.76 billion in 2029. The Gene Therapy in CNS Disorder Market is projected to reach USD 13.86 billion by 2025 and USD 191.04 billion by 2035. The United States is a leading region for gene therapy in CNS disorders.
AI Analysis | Feedback
Editas Medicine (EDIT) is a clinical-stage genome editing company primarily focused on developing transformative genomic medicines. Over the next 2-3 years, the company's revenue growth is expected to be driven by a combination of its lead clinical programs and strategic collaborations. Here are 3-5 expected drivers of future revenue growth for Editas Medicine: * Advancement and Potential Commercialization of EDIT-401 for Heterozygous Familial Hypercholesterolemia (HeFH): Editas Medicine has designated EDIT-401 as its lead *in vivo* development candidate, targeting heterozygous familial hypercholesterolemia (HeFH). Preclinical studies for EDIT-401 have shown significant reduction in LDL cholesterol levels. The company anticipates submitting an Investigational New Drug (IND) or Clinical Trial Application (CTA) by mid-2026, with plans to initiate the first-in-human clinical trial in HeFH patients later in 2026. Early human proof-of-concept data is targeted by year-end 2026, and topline dose-finding results are expected in 2027. Successful progression through these clinical milestones could pave the way for future product revenue or significant partnership deals. * Growth in Collaboration and Licensing Revenue from Strategic Partnerships: As a pre-commercial biotechnology company, Editas Medicine relies on revenue generated from collaboration agreements and licensing its proprietary CRISPR technology. The company has recognized revenue from milestone achievements in existing collaborations, such as with Bristol Myers Squibb (BMS). Furthermore, a non-exclusive license agreement with Vertex Pharmaceuticals for Editas's Cas9 gene editing technology, which includes Vertex's CASGEVY™ for sickle cell disease and beta-thalassemia, provides for upfront payments, a contingent upfront payment, and annual license fees through 2034. Continued and expanded strategic alliances are crucial for sustained revenue growth. * Continued Clinical Progress and Potential Milestone Payments from EDIT-101 for Leber Congenital Amaurosis 10 (LCA10): EDIT-101, an experimental CRISPR-based medicine for Leber Congenital Amaurosis 10 (LCA10), remains in a Phase 1/2 clinical trial. Editas Medicine has a strategic alliance with Allergan Pharmaceuticals International Limited (now part of AbbVie) for the discovery, development, and commercialization of new gene editing medicines for ocular disorders. Under this agreement, Editas is eligible to receive development and commercial milestones, as well as royalty payments. Further positive clinical trial data and the achievement of development milestones for EDIT-101 could contribute to revenue growth in the next 2-3 years.AI Analysis | Feedback
Capital Allocation Decisions (2021-2025)
Share Issuance
- Editas Medicine generated $17.3 million in proceeds from sales of common stock under an at-the-market (ATM) facility after September 30, 2025.
- As of February 27, 2026, the company had 97,871,999 shares of common stock outstanding.
Inbound Investments
- Collaboration and other research and development revenues increased to $40.5 million for the full year 2025, up from $32.3 million in 2024. This increase was primarily due to the recognition of deferred revenue from a concluded collaboration agreement with a strategic partner and a milestone achieved in 2025 under a collaboration with Bristol Myers Squibb (BMS).
- In the third quarter of 2025, the company recognized $7.5 million in collaboration and other research and development revenues, largely attributed to a milestone payment from its agreement with Bristol Myers Squibb.
- A milestone payment was triggered in the second quarter of 2025 from the collaboration agreement with Bristol Myers Squibb, following the acceptance of the first Investigational New Drug (IND)/Clinical Trial Application (CTA) for the CD19 HD Allo CAR T program.
Outbound Investments
- Editas Medicine has made one investment in Nomad Health.
- The company has not made any acquisitions.
Capital Expenditures
- Editas Medicine expects its existing cash, cash equivalents, and marketable securities to fund its operating expenses and capital expenditure requirements into the third quarter of 2027.
- Capital expenditures are an ongoing requirement for the company, supporting the advancement of its in vivo gene editing programs, including lead candidate EDIT-401, through preclinical and clinical development.
Latest Trefis Analyses
Trade Ideas
Select ideas related to EDIT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
| 03312021 | EDIT | Editas Medicine | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 1.2% | -54.7% | -66.5% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 20.46 |
| Mkt Cap | 2.2 |
| Rev LTM | 54 |
| Op Inc LTM | -260 |
| FCF LTM | -263 |
| FCF 3Y Avg | -218 |
| CFO LTM | -255 |
| CFO 3Y Avg | -209 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.3% |
| Rev Chg 3Y Avg | 58.8% |
| Rev Chg Q | 44.2% |
| QoQ Delta Rev Chg LTM | 10.0% |
| Op Mgn LTM | -274.6% |
| Op Mgn 3Y Avg | -400.4% |
| QoQ Delta Op Mgn LTM | 180.5% |
| CFO/Rev LTM | -407.8% |
| CFO/Rev 3Y Avg | -409.3% |
| FCF/Rev LTM | -409.3% |
| FCF/Rev 3Y Avg | -420.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.2 |
| P/S | 16.4 |
| P/EBIT | -2.7 |
| P/E | -2.8 |
| P/CFO | -2.8 |
| Total Yield | -19.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -20.1% |
| D/E | 0.1 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.4% |
| 3M Rtn | 7.9% |
| 6M Rtn | -21.7% |
| 12M Rtn | 79.7% |
| 3Y Rtn | -37.6% |
| 1M Excs Rtn | 2.5% |
| 3M Excs Rtn | 7.6% |
| 6M Excs Rtn | -29.5% |
| 12M Excs Rtn | 64.9% |
| 3Y Excs Rtn | -98.8% |
Comparison Analyses
Price Behavior
Price Behavior
| Market Price | $2.94 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 02/03/2016 | |
| Distance from 52W High | -29.2% | |
| 50 Days | 200 Days | |
| DMA Price | $2.21 | $2.60 |
| DMA Trend | up | up |
| Distance from DMA | 33.2% | 13.0% |
| 3M | 1YR | |
| Volatility | 92.4% | 95.6% |
| Downside Capture | 0.38 | 1.11 |
| Upside Capture | 373.27 | 259.97 |
| Correlation (SPY) | 36.7% | 33.3% |
EDIT Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.29 | 3.33 | 2.70 | 2.21 | 1.92 | 2.01 |
| Up Beta | 10.39 | 6.12 | 6.99 | 2.37 | 1.87 | 1.90 |
| Down Beta | 1.07 | 2.20 | 1.29 | 1.98 | 1.43 | 1.65 |
| Up Capture | 645% | 571% | 393% | 199% | 606% | 803% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 9 | 19 | 27 | 52 | 113 | 325 |
| Down Capture | 185% | 189% | 170% | 201% | 151% | 113% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 10 | 20 | 31 | 67 | 128 | 408 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDIT | |
|---|---|---|---|---|
| EDIT | 203.7% | 98.0% | 1.57 | - |
| Sector ETF (XLV) | 12.3% | 16.8% | 0.52 | 38.1% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | 36.4% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | 14.7% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | 7.0% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 32.5% |
| Bitcoin (BTCUSD) | -4.3% | 43.7% | 0.02 | 35.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDIT | |
|---|---|---|---|---|
| EDIT | -41.4% | 93.1% | -0.17 | - |
| Sector ETF (XLV) | 6.3% | 14.6% | 0.25 | 30.1% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 37.3% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | 8.4% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | 4.9% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 33.1% |
| Bitcoin (BTCUSD) | 4.3% | 56.5% | 0.30 | 25.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDIT | |
|---|---|---|---|---|
| EDIT | -22.3% | 83.4% | 0.06 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 33.5% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 37.7% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | 5.7% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 10.2% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 26.9% |
| Bitcoin (BTCUSD) | 67.6% | 66.9% | 1.07 | 18.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/9/2026 | 16.0% | 22.0% | 37.0% |
| 11/10/2025 | 2.0% | 5.3% | 5.3% |
| 8/12/2025 | 34.5% | 14.8% | 18.3% |
| 5/12/2025 | -2.6% | -3.2% | 31.8% |
| 1/13/2025 | -7.9% | -3.2% | -6.3% |
| 10/22/2024 | -12.5% | -13.3% | -34.0% |
| 8/7/2024 | -12.2% | -14.7% | -25.4% |
| 5/8/2024 | -11.4% | 0.0% | -4.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 12 | 11 |
| # Negative | 9 | 11 | 12 |
| Median Positive | 9.7% | 9.4% | 23.8% |
| Median Negative | -5.8% | -5.4% | -17.4% |
| Max Positive | 34.5% | 45.1% | 58.3% |
| Max Negative | -12.5% | -15.9% | -34.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/05/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/9/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | |||||||
Prior: Q3 2025 Earnings Reported 11/10/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | 2,027 | -0.0% | Lowered | Guidance: 2,027 for 2027 | |||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 12042025 | 2.15 | 713 | 1,535 | 148,084 | Form |
| 2 | O'Neill, Gilmore Neil | CEO | Direct | Sell | 12042025 | 2.15 | 5,603 | 12,064 | 579,371 | Form |
| 3 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 12042025 | 2.15 | 461 | 993 | 34,252 | Form |
| 4 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 9042025 | 2.60 | 710 | 1,843 | 180,403 | Form |
| 5 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 9042025 | 2.60 | 458 | 1,189 | 42,496 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.